SCHEMBL4675975

SCHEMBL4675975

COc1ccc(Cc2csc(C(=O)/C=C(\O)C(=O)O)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.43
MAPT P10636 2/20 0.43
LTA4H P09960 2/20 0.42
SAE1 Q9UBE0 1/20 0.42
UBA2 Q9UBT2 1/20 0.42
ALDH1A1 P00352 4/20 0.39
HPGD P15428 1/20 0.39
LMNA P02545 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
LDHA P00338 1/20 0.38
CTBP2 P56545 1/20 0.38
GAA P10253 1/20 0.38
ALOX12 P18054 1/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675978 1.00 NPSR1 (0.43) NPSR1MAPTLTA4HSAE1UBA2
SCHEMBL4673052 0.86 MAPT (0.46) NPSR1MAPTLTA4HALDH1A1HPGD
SCHEMBL4673048 0.86 MAPT (0.46) NPSR1MAPTLTA4HALDH1A1HPGD
SCHEMBL4674028 0.84 DAO (0.49) NPSR1MAPTHPGDLMNAPOLB
SCHEMBL4674025 0.84 DAO (0.49) NPSR1MAPTHPGDLMNAPOLB
SCHEMBL4671625 0.84 MAPT (0.51) NPSR1MAPTALDH1A1HPGDLMNA
SCHEMBL4671628 0.84 MAPT (0.51) NPSR1MAPTALDH1A1HPGDLMNA
SCHEMBL4675253 0.83 MAPT (0.43) NPSR1MAPTALDH1A1HPGDNPC1
SCHEMBL4675249 0.83 MAPT (0.43) NPSR1MAPTALDH1A1HPGDNPC1
SCHEMBL4674875 0.83 MAPT (0.43) NPSR1MAPTLTA4HALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 NPSR1 937/4885MAPT 205/4885LTA4H 2809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.